A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) With Advanced Hepatic Fibrosis
Latest Information Update: 29 Dec 2023
At a glance
- Drugs Belapectin (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors Galectin Therapeutics
- 14 Nov 2023 Results assessing to measure the serum galectin-3 in portal hypertension due to nonalcoholic steatohepatitis from NCT01899859 (n=31) and NCT02462967 (n=162) studies, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 24 Oct 2016 Results published in the Alimentary Pharmacology and Therapeutics
- 07 Jan 2015 Status changed from recruiting to completed, according to a Galectin Therapeutics media release.